EGI
CSTL icon

EAM Global Investors’s Castle Biosciences CSTL Stock Holding History

EAM Global Investors’s Portfolio CSTL Stock Details CSTL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q1 		– Sell
-37,141
Closed -$2.49M – 151
2020
Q4 		$2.49M Sell
37,141
-19,335
-34% -$1.05M 0.68% 78
2020
Q3 		$2.91M Hold
56,476
– – 1.07% 27
2020
Q2 		$2.13M Hold
56,476
– – 0.96% 38
2020
Q1 		$1.68M Buy
56,476
+7,119
+14% +$215K 0.99% 38
2019
Q4 		$1.7M Buy
49,357
+5,383
+12% +$132K 0.68% 81
2019
Q3 		$795K Buy
+43,974
New +$975K 0.39% 104

Other funds holding CSTL

AIM
ARK Investment Management St. Petersburg, Florida $12.9B AUM 64.92% 1-Year Est. Return
WA
Wasatch Advisors Salt Lake City, Utah $15.3B AUM 25.06% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
MCMC
Matrix Capital Management Company Portsmouth, New Hampshire $46.3M AUM 114.38% 1-Year Est. Return
HCMT
Highland Capital Management (Texas) Dallas, Texas $39M AUM
RI
RTW Investments New York $10B AUM 135.35% 1-Year Est. Return
Wells Fargo
Wells Fargo San Francisco, California $530B AUM 22.01% 1-Year Est. Return
PM
Pembroke Management Montreal, Quebec, Canada $691M AUM 27.96% 1-Year Est. Return

EAM Global Investors's CSTL Position: Q1 2021 in Review

EAM Global Investors sold out of Castle Biosciences (CSTL) in Q1 2021, closing a stake of 37,141 shares — an estimated $2.49M sold.

EAM Global Investors first reported a position in CSTL in Q3 2019 and held it in 6 quarters. The position peaked at $2.91M in Q3 2020. 175 funds tracked by Wall St. Rank hold CSTL as of Q1 2021.

  • EAM Global Investors reported no remaining Castle Biosciences position as of Q1 2021 after selling out during the quarter.
  • EAM Global Investors sold 37,141 Castle Biosciences shares in Q1 2021, an estimated $2.49M.
  • EAM Global Investors first reported a position in Castle Biosciences in Q3 2019 and held it in 6 quarters.
  • EAM Global Investors's Castle Biosciences position peaked at $2.91M in Q3 2020.
  • 175 funds tracked by Wall St. Rank held Castle Biosciences as of Q1 2021.

Based on EAM Global Investors's 13F filing for Q1 2021, filed 11 May 2021.